semaglutide injections miami Weight Loss Miami, FL |

MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group

Based on the STEP 1 clinical trial, patients lost approximately 2% of body weight per month for the first six months, slowing to about 1% per month thereafter, reaching an average of ~1516% total body weight loss by week 68

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)

While Ozempic (semaglutide) is not indicated to treat psoriasis directly, emerging evidence suggests its anti-inflammatory properties may provide benefits independent of weight loss alone

Type 1 diabetes results from the bodys immune system destroying insulin-producing cells in the pancreas, leading to an absolute deficiency of insulin

Tesamorelin-Specific Considerations Tesamorelin can mildly elevate fasting glucose and HbA1c in some patients